

Amendments of the Claims:

A detailed listing of all claims in the application is presented below. This listing of claims will replace all prior versions, and listings, of claims in the application. All claims being currently amended are submitted with markings to indicate the changes that have been made relative to immediate prior version of the claims. The changes in any amended claim are being shown by strikethrough (for deleted matter) or underlined (for added matter).

1. (Original) A preventive or therapeutic agent for chronic obstructive pulmonary disease containing polypeptide of the thioredoxin superfamily.
2. (Original) The preventive or therapeutic agent of claim 1, wherein said chronic obstructive pulmonary disease is accompanied by infiltration of neutrophils and lymphocytes into lung cells.
3. (Currently Amended): The preventive or therapeutic agent of ~~either~~ claim ~~1~~ or 2, wherein said chronic obstructive pulmonary disease is caused by smoking or by pollutants in the air.
4. (Cancelled).
5. (Cancelled).
6. (Cancelled).
7. (Cancelled).
8. (New) The preventive or therapeutic agent of claim 2, wherein said chronic obstructive pulmonary disease is caused by smoking or by pollutants in the air.
9. (New) The preventive or therapeutic agent of claim 3, wherein said pollutants in the air are selected from a group consisting of fine particles in tobacco smoke, fine particles in exhaust gas, dust, and fine particles in soot.
10. (New) The preventive or therapeutic agent of claim 8, wherein said pollutants in the air are selected from a group consisting of fine particles in tobacco smoke, fine particles in exhaust gas, dust, and fine particles in soot.

11. (New) The preventive or therapeutic agent according to claim 1, wherein said chronic obstructive pulmonary disease is either pulmonary emphysema or chronic bronchitis.
12. (New) The preventive or therapeutic agent according to claim 2, wherein said chronic obstructive pulmonary disease is either pulmonary emphysema or chronic bronchitis.
13. (New) The preventive or therapeutic agent according to claim 3, wherein said chronic obstructive pulmonary disease is either pulmonary emphysema or chronic bronchitis.
14. (New) The preventive or therapeutic agent according to claim 8, wherein said chronic obstructive pulmonary disease is either pulmonary emphysema or chronic bronchitis.
15. (New) The preventive or therapeutic agent according to claim 9, wherein said chronic obstructive pulmonary disease is either pulmonary emphysema or chronic bronchitis.
16. (New) The preventive or therapeutic agent according to claim 10, wherein said chronic obstructive pulmonary disease is either pulmonary emphysema or chronic bronchitis.
17. (New) The preventive or therapeutic agent according to claim 1, wherein said chronic obstructive pulmonary disease is accompanied by one of the symptoms selected from a group consisting of inflammation, fibrosis, and necrosis in tissues and cells.
18. (New) The preventive or therapeutic agent according to claim 2, wherein said chronic obstructive pulmonary disease is accompanied by one of the symptoms selected from a group consisting of inflammation, fibrosis, and necrosis in tissues and cells.
19. (New) The preventive or therapeutic agent according to claim 3, wherein said chronic obstructive pulmonary disease is accompanied by one of the symptoms selected from a group consisting of inflammation, fibrosis, and necrosis in tissues and cells.
20. (New) The preventive or therapeutic agent according to claim 8, wherein said chronic obstructive pulmonary disease is accompanied by one of the symptoms selected from a group consisting of inflammation, fibrosis, and necrosis in tissues and cells.

21. (New) The preventive or therapeutic agent according to claim 9, wherein said chronic obstructive pulmonary disease is accompanied by one of the symptoms selected from a group consisting of inflammation, fibrosis, and necrosis in tissues and cells.
22. (New) The preventive or therapeutic agent according to claim 10, wherein said chronic obstructive pulmonary disease is accompanied by one of the symptoms selected from a group consisting of inflammation, fibrosis, and necrosis in tissues and cells.
23. (New) The preventive or therapeutic agent according to claim 11, wherein said chronic obstructive pulmonary disease is accompanied by one of the symptoms selected from a group consisting of inflammation, fibrosis, and necrosis in tissues and cells.
24. (New) The preventive or therapeutic agent according to claim 12, wherein said chronic obstructive pulmonary disease is accompanied by one of the symptoms selected from a group consisting of inflammation, fibrosis, and necrosis in tissues and cells.
25. (New) The preventive or therapeutic agent according to claim 13, wherein said chronic obstructive pulmonary disease is accompanied by one of the symptoms selected from a group consisting of inflammation, fibrosis, and necrosis in tissues and cells.
26. (New) The preventive or therapeutic agent according to claim 14, wherein said chronic obstructive pulmonary disease is accompanied by one of the symptoms selected from a group consisting of inflammation, fibrosis, and necrosis in tissues and cells.
27. (New) The preventive or therapeutic agent according to claim 15, wherein said chronic obstructive pulmonary disease is accompanied by one of the symptoms selected from a group consisting of inflammation, fibrosis, and necrosis in tissues and cells.
28. (New) The preventive or therapeutic agent according to claim 16, wherein said chronic obstructive pulmonary disease is accompanied by one of the symptoms selected from a group consisting of inflammation, fibrosis, and necrosis in tissues and cells.
29. (New) The preventive or therapeutic agent according to claim 1, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.

30. (New) The preventive or therapeutic agent according to claim 2, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
31. (New) The preventive or therapeutic agent according to claim 3, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
32. (New) The preventive or therapeutic agent according to claim 8, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
33. (New) The preventive or therapeutic agent according to claim 9, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
34. (New) The preventive or therapeutic agent according to claim 10, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
35. (New) The preventive or therapeutic agent according to claim 11, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
36. (New) The preventive or therapeutic agent according to claim 12, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
37. (New) The preventive or therapeutic agent according to claim 13, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
38. (New) The preventive or therapeutic agent according to claim 14, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
39. (New) The preventive or therapeutic agent according to claim 15, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
40. (New) The preventive or therapeutic agent according to claim 16, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
41. (New) The preventive or therapeutic agent according to claim 17, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.

42. (New) The preventive or therapeutic agent according to claim 18, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
43. (New) The preventive or therapeutic agent according to claim 19, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
44. (New) The preventive or therapeutic agent according to claim 20, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
45. (New) The preventive or therapeutic agent according to claim 21, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
46. (New) The preventive or therapeutic agent according to claim 22, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
47. (New) The preventive or therapeutic agent according to claim 23, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
48. (New) The preventive or therapeutic agent according to claim 24, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
49. (New) The preventive or therapeutic agent according to claim 25, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
50. (New) The preventive or therapeutic agent according to claim 26, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
51. (New) The preventive or therapeutic agent according to claim 27, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.
52. (New) The preventive or therapeutic agent according to claim 28, wherein said polypeptide of the thioredoxin superfamily is human thioredoxin.